About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The VHIR Infectious Diseases research group is made up of medical professionals, with healthcare and clinical or basic translational research activities; of Biomedicine dedicated to basic research; and Nursing, with activities to support clinical research.
The group's lines of research are mainly focused on four areas:
Infections related to immunosuppression. Includes infectious diseases related to immunocompromised patients, solid organ or hematopoietic stem cell transplant recipients and recipients of biological therapies.
Sexually transmitted diseases, including HIV infection and other highly prevalent infections in our country (syphilis, gonorrhea, lymphogranuloma venere or infections caused by the human papillomavirus).
Infections related to health care, with special emphasis on those difficult to treat (cardiovascular infections or infections related to prosthetic materials) or caused by multi-resistant pathogens (MDRO) or affecting vulnerable populations.
Global Health and Tropical Diseases with special emphasis on prevalent diseases in our environment that affect the immigrant or displaced population.
PMID: 30614744 Journal: EXPERT OPINION ON PHARMACOTHERAPY Year: 2019 Reference: Expert Opin Pharmacother. 2019 Mar;20(4):423-434. doi: 10.1080/14656566.2018.1559820. Epub 2019 Jan 7. Impact factor: 3.038 Publication type: Review in international publication Authors: Burgos, Joaquin, Almirante, Benito, Falco, Vicenc et al. DOI: 10.1080/14656566.2018.1559820
PMID: 30537648 Journal: JOURNAL OF CLINICAL VIROLOGY Year: 2019 Reference: J Clin Virol. 2019 Jan;110:45-50. doi: 10.1016/j.jcv.2018.11.010. Epub 2018 Dec 1. Impact factor: 3.02 Publication type: Paper in international publication Authors: Len, Oscar, Perello, Manel, Torres, Irina B, Codina, Gemma, Esperalba, Juliana, Sellares, Joana, Moreso, Francesc, Seron, Daniel, Gavalda, Joan, Los-Arcos, Ibai et al. DOI: 10.1016/j.jcv.2018.11.010
The new protocol has the same efficacy as the standard one, but only a quarter of the duration, reducing dropout rates and side effects.
The initiative, carried out at the Consulate of Bolivia, has resulted in 307 new tests for the diagnosis of Chagas disease
The study shows that blocking the KLRG1 receptor helps to recover the activity of the natural killer cells of the immune system and reactivate the virus reservoir to fight infection.
